Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Latest Information Update: 02 Feb 2025
Price :
$35 *
At a glance
- Drugs Epcoritamab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 02 Feb 2025 New trial record